Das fibrinolytische System

• LITERATUR

• 1 Adelman B, Michelson A D, Loscalzo J, Greenberg J, Handin R I. Plasmin effect on platelet glycoprotein IB von Willebrand factor interactions. Blood 1985; 65: 32-40.
• 2 Andrade-Gordon P, Strickland S. Studies on the interaction between plasminogen and heparin. Embo Workshop on plasminogen activation. Amalfi; Italy: 1985. Abst.
• 3 Aoki N, von Kaulla K N. Human serum plasminogen antiactivator: its distinction from antiplasmin. Am J Physiol 1971; 220: 1137-45.
• 4 Astedt B, Lecander I, Brodin T, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-5.
• 5 Astrup T. Fibrinolysis an overview. In: Progress in Chemical Fibrinolysis and Thrombolysis.. Davidson J F, Rowan R M, Samama M M, Desnoyers P C. 1978. 03 1-57.
• 6 Astrup T. Tissue activators of plasminogen. Fed Proc 1966; 25: 42-51.
• 7 Banyai L, Vâradi A, Patthy L. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator. FEBS Letters 1983; 163 1: 37-41.
• 8 Bauer P I, Machovich R, Bûki K G, Csonka E, Koch S A, Horvath I. Interaction of plasmin with endothel cells. Biochem J 1984; 218: 119-24.
• 9 Beers W H, Strickland S, Reich E. Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell 1975; 06: 387-94.
• 10 Bergsdorf N, Nilsson T, Wallén P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic diseases. Thromb Haemostas 1983; 50: 740-4.
• 11 Bernik M B, Kwaan H C. Origin of fibrinolytic activity in culture of human kidney. J Lab Clin Med 1967; 70: 650.
• 12 Booth N A, Anderson J A, Bennett B. Platelet release protein which inhibits plasminogen activators. J Clin Pathol 1985; 38: 825-30.
• 13 Camiolo S M, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin and plasmin. Proc Soc Exper Biol Med 1971; 138: 277-80.
• 14 Christensen U, Clemmensen I. Kinetic properties of the primary inhibitor of plasmin from human plasma. Biochem J 1971; 163: 389-91.
• 15 Cieplak W, Hart D A. Formation of stable complexes between urokinase and a human urinary component. Thromb Haemostas 1985; 53: 36-41.
• 16 Claeys H, Vermylen J. Physico-chemical and proenzyme properties of NH₂-terminal glutamic acid and NH₂-terminal lysin human plasminogen. Influence of 6-aminohexanoic acid. Biochim Biophys Acta 1974; 342: 351-9.
• 17 Collen D, Verstraete M. Molecular biology of human plasminogen. II Metabolism in physiological and some pathological conditions in man. Thromb Diath haemorrh 1975; 34: 403-8.
• 18 Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
• 19 Collen D, Wiman B. Fast acting plasmin inhibitor in human plasma. Blood 1978; 51: 563-9.
• 20 Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53: 313-24.
• 21 Collen D, De Cock F, Lijnen H R. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. Thromb Haemostas 1984; 52: 24-6.
• 22 Collen D, Zamarron C, Lijnen H R, Hoylaerts M. Activation of plasminogen by pro-urokinase II. Kinetics. J Biol Chem 1986; 261: 1259-66.
• 23 Colucci M, Paramo J A, Collen D. Generation in plasma of a fast-acting inhibitor activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
• 24 Dano K, Andreasen P A, Grondahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
• 25 Deguchi K, Murashima S, Shirakawa S, Soria C, Soria J, Dunn F, Tobelem G. The potentiating effect of platelet on plasminogen activation by tissue plasminogen activator. Thromb Res 1985; 40: 853-61.
• 26 Drapier J C, Petit J F. Involvement of prostaglandins in LPS-mediated of plasminogen activator synthesis by inflammatory macrophages. Int J Immunopharmac 1984; 06: 345-50.
• 27 Emeis J J, van den Hoogen C N, Jense D. Hepatitic clearance of tissue-type plasminogen activator. Thromb Haemost 1985; 54: 661-4.
• 28 Erickson L A, Ginsberg M H, Loskutoff D J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
• 29 Erickson L A, Heckmann C M, Loskutofff D J. The primary plasminogen-activator inhibitor in endothelial cells, platelets, serum and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-4.
• 30 Fuchs H E, Berger H, Pizzo S V. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-44.
• 31 Gordon S, Unkeless J C, Cohn Z A. Induction of macrophage plasminogen activator by endotoxin stimulation and phagocytosis. J Exp Med 1974; 140: 995-1010.
• 32 Granelli-Piperno A, Vassalli J D, Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. J Exp Med 1977; 146: 1693-706.
• 33 Groskopf W R, Summaria L, Robbins K C. Studies on the active center of human plasmin. Partial amino acid sequence of a peptide containing the active center serine residue. J Biol Chem 1969; 244: 3590-7.
• 34 Giinzler W A, Steffens G J, Ötting F, Buse G, Flohé L. Structural relationship between human high and low molecular mass urokinase. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 133-41.
• 35 Giinzler W A, Steffens G J, Ötting F, Kim S M, Frankus E, Flohé L. The primary structure of high molecular mass urokinase from human urine. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 1155-65.
• 36 Gurewich V, Pannell R, Lovie S, Kelley P, Suddith R L, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase : A study in vitro and in two chemical species. J Clin Invest 1984; 73: 1731-9.
• 37 Hamilton J A, Ralph P, Moore M A. A macrophage tumor cell line and plasminogen activator. J Exp Med 1978; 147: 811-6.
• 38 Harpel P C. α₂-Plasmin inhibitor and α₂macroglobulin-plasmin complex in plasma. J Clin Invest 1981; 68: 46-55.
• 39 Holmberg L, Lecander I, Persson B, Ästedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-37.
• 40 Hoylaerts M, Rijken D C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982; 257: 2912-9.
• 41 Huber R, Bode W. Activation, action and inhibition of trypsin deduced from the three dimensional structures of trypsinogen, trypsin and their complexes with the basic pancreatic trypsin inhibitor. In: Regulatory Proteolytic Enzymes and Their Inhibitors. Magnusson S. (Ed). Oxford: Pergamon Press; 1978: 15-34.
• 42 Husain S S, Lipinski B, Gurewich V. Rapid purification of a high affinity plasminogen activator from human blood by specific adsorption on fibrin/Celite. Proc Natl Acad Sci USA 1981; 78: 4265-6269.
• 43 Husain S S, Gurewich V, Lipinski B. Purification of a new high molecular weight form of urokinase from urine. Thromb Haemostas. 1981 46. 11 Abst. 16.
• 44 Ichinose A, Tamaki T, Aoki N. Factor Xlll-mediated cross-linking of NH₂-terminal peptide of α₂-plasmin inhibitor to fibrin. FEBS Letters 1983; 153: 369-71.
• 45 Kagitani H, Tagawa M, Hatanaka K, Ikari T, Saito A, Bando H, Okada K, Matsuo O. Expression in E. coli of finger domain lacking tissue-type plasminogen activator with high fibrin affinity: FEBS Letters. 1985; 189 1: 145-9.
• 46 Jones C M, Taramelli D, Clouse C A, Goldfarb R G. Role of bacterial lipopolysaccharide and lymphokine in the regulation of macrophage activation : Correlates between secretion of plasminogen activator and tumor lysis. Immunobiol 1984; 166: 410-27.
• 47 Ichinose A, Kisiel W, Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Letters 1984; 175: 412-8.
• 48 Kaplan A P, Silverberg M, Dunn J T, Ghebretiwet B. Interaction of the clotting, kinin-forming complement and fibrinolytic pathways in inflammation. Ann NY Acad Sci USA 1982; 389: 25-38.
• 49 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single chain prourokinase induces conformational changes which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-81.
• 50 Keski-Oja J, Vaheri A. The cellular target for the plasminogen activator, urokinase in human fibroblast 66.000 dalton protein. Biochim Biophys Acta 1982; 720: 141-6.
• 51 Kluft C, Los P, Jie A F. The molecular form of α₂-antiplasmin with affinity for plasminogen in selectively bound to fibrin by F XIII. Thromb Res 1984; 33: 419-25.
• 52 Korninger C, Stassen J M, Collen D. Turnover of human extrinsic tissue type plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-61.
• 53 Lacroix M, Smith F E, Fritz I B. Changes in levels of plasminogen activator activity in normal and germ-cell-depleted testes during development. Mol Cell Endocrinol 1982; 26: 259-67.
• 54 Lecander I, Roblin R, Ästedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984; 57: 407-12.
• 55 Lecander I, Ästedt B. Isolation of a new specific plasminogen activator inhibitors from pregnancy plasma. Br J Haematol 1982; 62: 221-8.
• 56 Levin E G, Marzee V, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988-95.
• 57 Lijnen H R, Wiman B, Collen D. Partial primary structure of human α₂-antiplasmin. Homology with other plasma protease inhibitors. Thromb Haemostas 1982; 48: 311-4.
• 58 Lijnen H R, Zamarron C, Collen D. Characterization of the high-affinity interaction between human plasminogen and pro-urokinase. Eur J Biochem 1985; 150: 141-4.
• 59 Lijnen H R, Zamarron C, Blaber M, Winkler M E, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261: 1253-8.
• 60 Liotta L A, Goldfarb R H, Brundage R, Siegal G P, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase) plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-36.
• 61 Loskutoff D J, van Mourik J A, Erikson L A, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-60.
• 62 Macfarlane R G, Pilling J. Fibrinolytic activity of normal urine. Nature 1947; 159: 779.
• 63 Markus G, De Pasquale J L, Wissler F C. Quantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem 1978; 253: 727-32.
• 64 Matsuo O. Turnover of tissue plasminogen activator in man. Thromb Haemostas 1982; 48: 242.
• 65 Matsuo O, Kato K, Mihara H, Okuno S, Matsuo T. Determinaton of α₂-plasmininhibitor in body fluids. Thromb Res 1982; 27: 555-62.
• 66 Mochan E, Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta 1984; 800: 312-5.
• 67 Moonen G, Grau-Wagemans M P, Selak I. Plasminogen-activator-plasmin system and neuronal migration. Nature 1982; 298: 753-5.
• 68 Moroi M, Aoki N. Inhibition of plasminogen binding to fibrin by α₂-plasmin-inhibitor. Thromb Res 1977; 10: 851-6.
• 69 Moroi M, Aoki N. Isolation and characterization of α₂-plasmin-inhibitor from human plasma. J Biol Chem 1976; 251: 5956-65.
• 70 Moroz L A. Mini-Plasminogen : a mechanism for leucozyte modulation of plasminogen activation by urokinase. Blood 1981; 58: 97-104.
• 71 Miillertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-53.
• 72 Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49-53.
• 73 Nilsson S, Einarsson M, Ekvärn S, Häggroth Mattson C h. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 1985; 39: 511-21.
• 74 Pâques E P, Stöhr H-A, Stauß H, Heimburger N. Study of the stimulation of the plasminogenolytic activity of t-PA and u-PA by several substances. EMBO Workshop on Plasminogen Activation. Amalfi; Italy: 1985. Abst.
• 75 Pâques E P, Stöhr H-A, Heimburger N. Study of the mechanism of action of heparin on the fibrinolytic system : relationships between plasminogen activators and heparin. EMBO Workshop on Plasminogen Activation. Amalfi; Italy: 1985. Abst.
• 76 Pâques E P, Stöhr H-A, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: Relationship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807.
• 77 Patthy L, Trexler M, Vâli Z, Bânyai L, Vâradi A. Kringles: modules spezialized for protein binding. Homology of the gelatin-binding region of fibronectin with the kringle structure of proteases. FEBS Letters 1984; 171: 131-6.
• 78 Patthy L. Evolution of the proteases of blood coagulation, and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
• 79 Pennica D, Holmes W E, Kohr W J, Harkins R N, Vehar G A, Ward C A, Bennett W F, Yelverton E, Seeburg P H, Heyneker H L, Goeddel D V, Collen D. Cloning and expression of human tissuetype plasminogen activator c DNA in E. coli. Nature 1983; 301: 214-21.
• 80 Plow E F, Miles L A. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-11.
• 81 Pohl G, Kaplan L, Einarsson M, Wallén P, Jörnvall H. Differences between uterine and melanoma forms of tissue plasminogen activator. FEBS Letters 1984; 168: 29-32.
• 82 Râköczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295-300.
• 83 Rânby M, Bergsdorf N, Nilsson T. Enzymatic properties of the oneand two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175-83.
• 84 Rânby M. Studies on the kinetics plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-9.
• 85 Reich E. Plasminogen activator: secretion by neoplastic cells and macrophages. In: Reich E, Rifkin D B, Shaw E. (Eds.) Proteases and Biological Control. Cold Spring Harbor Laboratory. 1975: 333-41.
• 86 Reich E. Activation of plasminogen: a widespread mechanism for generating localized extracellular proteolysis. In: Rudden R W. (Ed.) Biological Markers of Neoplasia: Basic and Applies Aspects. New York: Elsevier; 1978: 491-500.
• 87 Remmie P S, Bouffard R, Bruchovsky N, Cheng H. Increased activity of plasminogen activators during involution of the rate ventral prostate. Biochem J 1984; 221: 171-8.
• 88 Rijken D C, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 267: 2920-35.
• 89 Robbins K C, Summaria L, Hsieh B, Shah R I. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 2421: 2333-42.
• 90 Russell J, Schneider A B, Katzhendler J, Kowalski K, Sherwood L M. Modification of human plancenta lactogen with plasmin. J Biol Chem 1979; 254: 2296-301.
• 91 Sakata Y, Curriden S, Lawrence D, Griffin J H, Loskutoff D L. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-5.
• 92 Saksela O, Hovi T, Vaheri A. Urokinasetype plasminogen activator and its inhibitor secreted by cultured human monocytes-macrophage. J Cell Physiol 1985; 122: 125-32.
• 93 Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 832: 35-65.
• 94 Sherman M I. Studies on the temporal correlation between secretion of plasminogen activator and stages of early mouse embryogenesis. Oncodevel Biol Med 1980; 01: 7-17.
• 95 Shimada H, Okamura H, Noda J, Suzuki A, Tojo S, Takada A. Plasminogen activator in rat ovary during the ovulation process: independence of prostaglandin mediation. J Endocrinol 1983; 97: 201-5.
• 96 Silverstein R L, Leung L L, Harpel P C, Nachman R L. Complex formation of platelet thrombospondin with plasminogen. J Clin Invest 1984; 74: 1625-33.
• 97 Sobel G W, Mohler S R, Jones N W, Dowdy A B, Guest M M. An activator of profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768.
• 98 Solomon J A, Chou I N, Schroder E W, Black P H. Evidence for a membrane association of plasminogen activator activity in mouse macrophages. Biochem Biophys Res Comm 1980; 94: 480-6.
• 99 Sottrup-Jensen L, Zajdel M, Claeys H, Petersen T E, Magnusson S. Amino-acid sequence of activation cleavage site in plasminogen: homology with “pro” part of prothrombin. Proc Natl Acad Sci USA 1975; 72: 2577-81.
• 100 Steffens G J, Giinzler W A, Ötting F, Frankus E, Flohé F. The complete amino acid sequence of low molecular mass urokinase from human urine. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 1043-58.
• 101 Stoppelli M P, Corti A, Soffientini A, Carsani G, Blasi F, Assoian R K. Differentiation enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U 937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-43.
• 102 Strickland S, Reich E, Sherman M I. Plasminogen activation in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 09: 231-40.
• 103 Strickland S, Beers W H. Studies on the role of plasminogen activator in ovulation : in vitro response of granulosa cells to gonadotropins cyclic nucleotides and prostaglandins. J Biol Chem 1976; 251: 5694-702.
• 104 Strickland S. Studies on the role of plasminogen activator in ovulation and embryogenesis. In: Magnusson S, Ottesen M, Fotman B, Dano K, Neurath H. (Eds.), Regulatory Proteolytic Enzymes and their Inhibitors. Oxford: Pergamon Press; 1978: 181-5.
• 105 Stump D, Thienpont C, Collen D. Urokinase-related proteins in human urine. J Biol Chem 1986; 261: 1267-73.
• 106 Stump D C, Lijnen H R, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J Biol Chem 1986; 261: 1274-8.
• 107 Takahashi K, Gojobori T, Naora H. Homology of kringle structures in urokinase and tissue-type plasminogen activator: the phylogeny with the related serine proteases. Cell Struct Funct 1985; 10: 209-18.
• 108 Thorsen S, Kok P, Astrup T. Reversible and irreversible alterations of human plasminogen indicated by changes in susceptibility to plasminogen activators and in response to epsilon-aminocaproic acid. Thromb Diath haemorrh 1974; 32: 325-40.
• 109 Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975; 393: 55-65.
• 110 Thorsen S, Philips M. Isolation of tissuetype plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-8.
• 111 Unkeless J C, Gordon S, Reich E. Secretion of plasminogen activator by stimulated macrophages. J Exp Med 1974; 139: 834-50.
• 112 Urdén G, Blombäck M. Determination of tissue plasminogen activator in plasma samples by means of a radioimmunoassay. Scand J Clin Lab Invest 1984; 44: 495-502.
• 113 Vaes G, Eeckhout J, Lenaers-Claeys G, Francois-Gillet C, Druetz C. The stimultaneous release by bone explants in culture and the parallel activation of procollagenase and of a latent-neutral proteinase that degrades cartilage proteoglycans and denatured collagen. Biochem J 1978; 172: 261-74.
• 114 Vassalli J D, Baccino D, Belin D. A novel function for the A chain of human urokinase; specific binding of Mr 55,000 UK to high affinity cell surface sites. Haemostasis. 1984 14. Abst. 79.
• 115 Virji M A, Vassalli I D, Estensen D, Reich E. Plasminogen activator of islets of Langerhans: Modulation by glucose and correlation with insulin production. Proc Natl Acad Sci USA 1980; 77: 875-9.
• 116 Wallén P, Wiman B. Characterization of human plasminogen. II Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta 1972; 257: 122-34.
• 117 Wallén P, Wiman B. On the generation pf intermediate plasminogen and its significance for activation. In: Reich E, Rifkin D B, Shaw E. (Eds.). Proteases and Biological Control. Cold Spring Harbor Laboratory; 1975: 291-303.
• 118 Wallén P, Bergsdorf N, Rânby M. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982; 719: 318-28.
• 119 Werb Z, Mainardi C L, Vater C A. Harris Endogeneous activation of latent collagenase by rheumatoid synovial cells. N Engl J Med 1977; 296: 1017-23.
• 120 Wiman B, Wallén P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 1977; 10: 213-22.
• 121 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
• 122 Wiman B, Lijnen H R, Collen D. On the specific interaction between the lysinebinding site in plasmin and complementary sites in α₂-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-54.
• 123 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast-inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-6.
• 124 Wun T C, Schleuning W D, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-83.
• 125 Zamarron C, Lijnen H R, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue plasminogen activator. J Biol Chem 1984; 259 4: 2080-3.